biote Corp. (BTMD) stock intrinsic value fair value estimate & owner earnings analysis

Biote trains and certifies independent physicians, nurse practitioners and other clinicians to offer bioidentical hormone pellet therapy, and sells those practices the hormone pellets, procedure kits and disposable trocars they use, plus a line of Biote-branded dietary supplements. The pellets are compounded drugs rather than FDA-approved products; they come from outside compounding pharmacies and, increasingly, from the company's own outsourcing facility, Asteria Health. Revenue in 2025 was $192.2 million, roughly three-quarters from pellet procedures and most of the rest from supplements. What has changed since our previous estimate. We previously treated the 2023-2025 level of cash earnings as the company's normal earning power and valued the shares at about $9.50 in the middle case. The first half of 2026 shows that level no longer holds. Revenue fell 8.9% to $89.2 million. Procedure revenue fell 13.9% in the second quarter to $30.3 million, or about 9% if you exclude the roughly $3.3 million of sales lost to the January 2026 voluntary recall of pellets shipped by Asteria Health between May 2025 and January 2026 because of possible metal particles. Gross margin fell from about 73% to 67% as the company bought replacement pellets from outside suppliers at higher cost. Selling, general and administrative costs rose from $50.9 million to $60.2 million, including a $5.1 million charge for legal settlements. Operating profit went from $20.5 million to a $0.3 million loss. Two consecutive weak quarters, following a $13.3 million drop in procedure revenue in 2025 that the company tied to fewer new clinics joining, are enough for us to lower the earnings level we start from. The earlier per-share figure for 2025 also counted some exchangeable units twice; correcting that raises 2025 cash earnings per share slightly but does not change the dollar figures used here. How we measure earnings. We start from operating cash flow, remove working-capital swings, and deduct stock compensation (about $7.5-9 million a year, a real cost to owners) and the capital spending needed to keep the business running. We then add back cash interest so the business is valued before its lenders, and subtract the debt separately. On that basis the business produced about $34 million in 2023, $29 million in 2024 and $36 million in 2025. In the first half of 2026 it lost about $6 million on the same basis, or roughly broke even after adding back the one-time legal settlements and the $2.2 million of costs the company attributes to the recall. That implies a current run rate of about $9 million a year. About $1-1.5 million of first-half operating cash outflow could not be matched to a specific line in the filings, and we have treated it as a cost. We assume about $4-6.5 million a year of upkeep capital spending, below the 2024-2026 level, which included building out Asteria. The debt. In May 2026 the company replaced its old term loan with a new Truist Bank facility: a fully drawn $125 million term loan and an undrawn $50 million revolver, both maturing May 8, 2031, at SOFR plus 2.50-2.75% (about 6.15% at June 30, close to our 6% valuation rate). With $11.2 million of cash, net debt is about $114 million and annual interest about $7.7 million. The loan caps total net leverage at 3.75 times EBITDA, falling to 3.25 times from December 31, 2027, and requires fixed-charge coverage of at least 1.25 times. Our own estimate of 2026 earnings before interest, taxes, depreciation, stock compensation and the one-time items is roughly $25-27 million, which puts leverage at about 4.2-4.5 times. The company was in compliance at June 30, but as the stronger 2025 quarters drop out of the calculation that cushion disappears, so an amendment, a waiver or a repricing looks likely. Bear case: procedure revenue keeps falling at the roughly 9% a year of the last two years, Asteria's cost disadvantage persists, legal costs continue at recent levels, and costs adjust only slowly. Cash earnings before interest fall to about $1.4 million next year and about zero the year after, then settle near $2 million a year once costs are cut. That does not cover the interest bill, so the leverage covenant is breached and lenders reprice or restructure the loan. We charge about $14 million for three extra points of interest through 2031. The business would be worth about $31 million against roughly $128 million owed, meaning the company would owe about $97 million more than it is worth, or about -$3.00 a share. In practice shareholders would likely be wiped out or heavily diluted. Base case: the one-time legal and recall costs do not recur, Asteria recovers half of its lost margin, and half of the recall-related sales return, for a starting level of about $14 million. Procedure revenue keeps shrinking but more slowly (8%, then 5%, then 3%) while clinic attrition stays around the 8% management reports, and each lost dollar of procedure revenue costs about 35 cents of profit. That gives cash earnings before interest of about $10.4 million, then $8.4 million, then a steady $7.2 million a year, which the recurring nature of pellet therapy across an established practitioner network sustains thereafter. The business is worth about $124 million. Subtracting about $114 million of net debt and about $3 million for the likely cost of amending the leverage covenant leaves about $7 million, or about $0.22 a share. In this case the business earns little more than its interest bill and cannot pay down the loan from its own cash. Bull case: Asteria's restored production (the company says it has added a second shift and is back to normal inventory levels) brings gross margin back to the roughly 71.5% earned in 2025, recall-related sales return in full, and procedure revenue declines only 4% and then 2% before holding steady. Cash earnings before interest are about $18 million next year, settling at about $17.3 million a year. The business is worth about $290 million. Less $114 million of net debt, that leaves about $176 million, or about $5.44 a share. Per-share values use about 32.3 million economic shares: roughly 27.1 million Class A shares plus 5.2 million units exchangeable into Class A. They exclude about 3.6 million earnout shares and units that vest only at share prices far above these values, as well as out-of-the-money options, whose cost is already covered by deducting stock compensation. What we did not credit: further growth in Biote-branded supplements (up 12% in the first half of 2026, but only a two-year record), the acquisitions management says it is evaluating, cost cuts beyond those described in the cases, and any return to the 2023-2025 earnings level, which was earned on a larger procedure business that has since shrunk. Management's adjusted earnings guidance was not used to set any figure. Risks and what could make this wrong: the business depends on continued access to compounded bioidentical hormones and on how regulators treat them. The recall shows how one manufacturing problem at the in-house facility can hit both margins and practitioner confidence. The company is run by an interim chief executive. It has also faced repeated litigation, including disputes with its founder that ended with the $18.5 million repurchase of his remaining shares in January 2026. On the upside, if the procedure decline stops quickly and margins recover in full, the value would sit near the bull case. The range of outcomes runs from shareholders being wiped out to about $5.44 a share, with the middle close to zero, so price alone does not establish a margin of safety. If the company shows two quarters of restored margins, stable procedure revenue and covenant compliance without lender relief, the margin-of-safety price is $1.75 a share. That leaves room for a 20% annual return while the debt is still outstanding.